The authors report a case of acute myocardial infarction following gemcitabine infusion and electrocardiographic abnormalities suggestive of ischemia on rechallenge of the drug. The possible underlying mechanisms of ischemia and/or infarction and the strate gies for prevention are discussed.
Get full access to this article
View all access options for this article.
References
1.
Cancer Medicine, ed. 4. 181:3211, 1997 .
2.
Carmichael J. , Fink U., et al: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer73:101-105, 1996.
3.
AHFS Drug Information, 1998, pp 830-831.
4.
Cortes-Funes H., Martin C., Abratt R., et al: Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs8:582-587, 1997.
5.
Pharmacology of Cancer Chemotherapy, ed. 2. 19.6: 445-446.
6.
Aapro MS, et al: Gemcitabine—a safety review. Anticancer Drugs9:191-201, 1998.
Ewer M., Benjamin R., Hong W., et al: Electrocardiographic changes in patients receiving chemotherapy with 5-flourouracil and cisplatinum with or without diethyldithiocarbamate . Proceedings of the 15th International Conference on Chemother apy, 1987, p 203.
9.
Oleksowicz L. , Bruckner H.: Prophylaxis of 5-flourouracil induced coronary vasospasm with calcium channel blockers. Am J Med85:750-751, 1988.
10.
Helson L.: Calcium channel blocker enhancement of anticancer drug toxicity—a review . Cancer Drug Deliv1:353-361, 1984.
